|12th November 2020||Sachs Group Inc Goldman||1,401,879||Other acquisition or disposition||$50.09||$70,220,119.11|
|28th September 2020||Sachs Group Inc Goldman||1,860||Exercise of in-the-money or at-the-money derivatives securities (usually options)||$0.00|
|22nd September 2020||Sachs Group Inc Goldman||1,013,165||Open or private sale||$19.00||$19,250,135.00|
|17th August 2020||Sachs Group Inc Goldman||1,500,000||Open or private sale||$27.50||$41,250,000.00|
|17th August 2020||Sachs Group Inc Goldman||225,000||Open or private sale||$27.50||$6,187,500.00|
|14th July 2020||Sachs Group Inc Goldman||100||Open or private sale||$25.40||$2,540.00|
|14th July 2020||Sachs Group Inc Goldman||300||Open or private purchase||$25.40||$7,620.00|
|14th July 2020||Sachs Group Inc Goldman||100||Open or private sale||$25.39||$2,539.00|
|14th July 2020||Sachs Group Inc Goldman||100||Open or private sale||$25.41||$2,541.00|
|10th July 2020||Sachs Group Inc Goldman||50,000||Open or private purchase||$28.04||$1,402,000.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
T2 Biosystems, Inc. engages in the development of proprietary technology platform. It offers the T2 Magnetic Resonance technology which enables rapid detection of pathogens, biomarkers and other abnormalities.